DNA epigenetic changes: a key cause of cancer
Analysis of cells shows many regions in DNA are differentially activated or inactivated in a cancer-specific manner.
List view / Grid view
Analysis of cells shows many regions in DNA are differentially activated or inactivated in a cancer-specific manner.
Scientists have discovered the motor protein dynein commands movement of cancer cells in soft tissue models, offering new clinical targets.
Researchers have found that reducing glycosylation on the T cell surface may offer new approaches to cancer immunotherapy.
Researchers have discovered a molecule that binds to a cancer cell protein, stopping growth of breast and ovarian tumours.
An epitope on CD95 receptor causes tumour cells to self-destruct and may prolong benefits of CAR T-cell therapy for solid tumours.
Extracellular vesicles loaded with mRNA encoding interferon-gamma offers promise for treating difficult tumours.
Bacteria programmed to paint targets on solid tumours for T cells to see eliminates the need for specific antigens.
A recent scientific collaboration, led by the Institute of Nuclear Physics of the Polish Academy of Sciences, has overcome measurement challenges, enabling reliable cancer diagnosis.
Midbody’s role in cell signalling and stimulating cell proliferation offers an opportunity to detect cancer.
A novel treatment approach using DON molecule starves tumours of essential nutrient, significantly slowing tumour growth.
Thousands of breast cancer gene expression signatures analysed.
Research suggests immune and non-immune cells can be reprogrammed by changing how nutrients are used.